D-K6L9
Product Specifications
UNSPSC Description
D-K6L9 shows antimicrobial and antibiofilm activities against P. aeruginosa from cystic fibrosis patients. D-K6L9 is stable and resistant to degradation by cystic fibrosis sputum proteases and will not induce bacterial resistance [1].
Target Antigen
Bacterial
Type
Peptides
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/d-k6l9.html
Solubility
10 mM in DMSO
Smiles
CC(C)C[C@@H](C(N)=O)NC([C@H](CC(C)C)NC([C@@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@@H](CCCCN)NC([C@@H](CC(C)C)NC([C@H](CC(C)C)NC([C@@H](CCCCN)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@@H](CC(C)C)NC([C@H](CCCCN)NC([C@@H](N)CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Molecular Weight
1804.48
References & Citations
[1]Ben Hur D, et al. Antimicrobial Peptides against Multidrug-Resistant Pseudomonas aeruginosa Biofilm from Cystic Fibrosis Patients. J Med Chem. 2022;65(13):9050-9062.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P5924A/D-K6L9-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P5924A/
Clinical Information
No Development Reported
CAS Number
426264-61-1
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
